Status: Baseline only
Increase the proportion of Medicare beneficiaries with sickle cell disease who receive disease modifying therapies
Baseline: 12.4 percent of Medicare beneficiaries aged 18 to 75 years with sickle cell anemia received disease modifying therapies in accordance with the National Heart, Lung, and Blood Institute (NHLBI)'s guidelines in 2016
Target: 15.9 percent
Data Source: Medicare Administrative Data, CMS
Sickle cell disease is the most common genetic blood disorder in the United States, and it’s more common in some racial/ethnic groups. It can affect every system in the body and cause severe acute and chronic pain. Evidence suggests that hydroxyurea, a recommended therapy that’s been used to treat sickle cell disease for decades, can help reduce complications.
Workgroup: Blood Disorders and Blood Safety Workgroup